Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact ...

Updated data from the phase 3 ENVISION trial (NCT05243550) point to sustained efficacy of mitomycin for intravesical solution (Zusduri; formerly UGN-102) in patients with recurrent low-grade, ...

Millennial urologists appear to have developed strong opinions on health policy as reflected by their recent social media activity, observes urologist Alan L. Kaplan, MD.

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

The phase 1/2 CaRe PC trial (NCT06056791) assessing INKmune in patients with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary end points, INmune Bio reported ...

In this video, Laura Bukavina, MD, MSc, MPH, and Betty Wang, MD, discuss the intersection of circulating tumor DNA (ctDNA) monitoring with emerging therapies for non–muscle invasive bladder cancer ...

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...

Howard B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.

In healthy aging men without developing diabetes mellitus, modest increases in HbA1c were linked with declines in sperm motility and erectile function.